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Background: To identify COPD associated gene susceptibility and lung function in a longitudinal cohort including
COPD and subjects who were at risk for developing COPD, and to replicate this in two cross-sectional and longitudinal
populations in Chinese Han population.
Methods: Three cohorts were recruited in this study, including an 18-year follow-up population (306 COPD and 743
control subjects) in one village in 1992 and it changed to 409 COPD and 611 controls in 2010, a 2 year follow-up study
in another village (374 COPD and 377 controls) and another 2 year follow-up one in a city (541 COPD and 560 controls)
in 2010. Sixteen candidate single nucleotide polymorphisms (SNPs) were selected for genotyping. Among them, 5SNPs
in or near HHIP, 1SNP in IREB2 and 1SNP in FAM13A were previously reported to be associated with COPD susceptibility
or lung function decline. And another 9SNPs were selected from HapMap website as HHIP tags. In 2010, totaling 1,324
COPD patients and 1,548 healthy controls were finally included in our genetic susceptibility analyses.
Results: We identified two new regions showing an association with COPD susceptibility in the Human Hedgehog
interacting protein (HHIP) rs11100865 and rs7654947, and we confirmed that the family with sequence similarity 13
member A gene (FAM13A) rs7671167 was associated with the development of COPD in Chinese Han population. And
the HHIP rs7654947 and FAM13A rs7671167 were associated with lung function decline, and this result was replicated
in other two populations.
Conclusions: These results suggest an important role of the HHIP and FAM13A regions as genetic risk factors for
COPD development and lung function decline in Chinese Han population. Future research on these genes should
focus on the molecular mechanisms of these genes on developing COPD and creating therapies to alleviate reduced
lung function.
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Chronic obstructive pulmonary disease (COPD) is a
leading global cause of morbidity and mortality, and will
become the fourth leading cause of death by the year
2030 [1]. Although cigarette smoking is the main patho-
logical driver of COPD, and more than 80% COPD pa-
tients are smokers, only a small proportion of smokers
develop clinically significant COPD. This suggests that a
genetic predisposition could explain why only a propor-
tion of cigarette smokers develop COPD. The alpha 1-
antitrypsin gene is the only gene that has been definitely
proven to influence COPD susceptibility, and present in
only 1-3% of individuals with COPD [2].
Recently, some large-scale genome-wide association
studies (GWAS) on COPD have identified susceptible
genes and loci associated with COPD [3-9], and these
genes play an important role in regulating morphogen-
esis and lung development, and are associated with the
presence of COPD and lung function decline. The vari-
ants of these genes may influence lung development and
are possibly related to COPD phenotype. However, all
the current gene susceptibility studies [3,4,7,10] in
COPD are cross-sectional, and smokers without COPD
were chosen as the controls. In the study period, these
“normal” controls without COPD may develop COPD
after 10 or 20 years. Therefore, there is likely to be some
bias with the cross-sectional studies in that these control
subjects may not necessarily lack the susceptibility
genes.
Moreover, GWAS on cross-sectional or longitudinal
lung function have identified some genes which are asso-
ciated with lung function, several previously unrecognized
loci related to two clinically important pulmonary func-
tions in a cross-sectional analysis [6,11-13]. Since these
studies only reflected the association of these genes and
lung function in the study period, they are limited for
evaluating the value of the screened genes involved in the
decline of lung function. Novel genes have also been iden-
tified by GWAS on longitudinal lung function in COPD
patient. However, the population which was recruited in
these studies either did not have any disease manifesta-
tions, or other respiratory diseases such as asthma, or they
did not have any subjects who had a high risk of develop-
ing COPD in their studies of lung function follow-up
[14-16]. Thus, genes identified in these studies may not
accurately reflect the association with lung function de-
cline in COPD. Our study focuses on a fixed cohort in a
Chinese village that includes subjects with COPD and
control subjects with similar risk factor for developing
COPD. These individuals were followed for up to 18 years.
We also replicated the study in two other validation co-
horts with extensive follow-up information and deter-
mined the association of the genes with forced expiratory
volume in one second (FEV1) decline.Our research presented here highlights an approach
that takes advantage of genome-wide association ana-
lyses using longitudinal and extensive follow-up data to
identify susceptibility genes in COPD that influence lung
function decline. This study identified two new loci and
confirmed one locus with the development of COPD,
and revealed one previously unreported locus and a
third locus associated with lung function in three inde-
pendent follow-up study cohorts.
Materials and methods
Study design and recruitment of subjects
In the first stage, study subjects were recruited from 15
villages in Haokou, Qianjiang, Hubei, China. We
screened subjects, from the population of 15 villages to-
taling 25,000 people to determine the risk groups and
subjects with COPD, as described in Figure 1. Of the
16,511 adults, 3,532 had a chronic cough longer than
2 years or a smoking history above 20 pack-years, who
might be suffering from COPD already or were at risk.
After performing lung function tests, as recommended
by the American Thoracic Society /European Respiratory
Society [17], 306 subjects with COPD and 743 age- and
gender- matched healthy subjects were enrolled in the
study after their consent was provided. The inclusion
and exclusion criteria of COPD subjects in this study
were described previously [18]. This was an 18-year lon-
gitudinal prospective study on COPD gene susceptibility
of the Chinese Han population which all subjects had a
lung function follow-up observation, and were tested
every five years. In the 18 year follow-up observation
period, there were cases and control subjects who could
not be enlisted through to the end. The main reasons
for the losses were that 9 cases and 16 control subjects
suffered from cancer or died with unknown causes. A
few individuals withdrew their consent or moved away
which resulted in lost contacts. Ultimately, there were
1,020 subjects who were enrolled and genotyped for the
study.
The replication cohorts were recruited from two dif-
ferent environmental living conditions and locations that
were different from the first cohort. The subjects with
COPD in the rural replication cohort were enlisted from
scattered rural areas in Hubei province except Haokou.
In the two replication cohorts, a total of 374 cases and
377 controls from the rural cohort, and 541 cases and
560 controls from the urban cohort in 2010 were en-
rolled and 205 COPD patients underwent lung function
follow-up observations for approximately 2 years. The
association of FEV1 decline with genetic variants was
also replicated in these individuals.
All the research procedures performed in this study
were screened and approved by the Research Ethics
Figure 1 The process of our study in the prospective follow-up stage. In the beginning (in 1992), COPD and controls who had same risk for
developing COPD were identified after the lung function performed. In the 18-year follow-up, some controls developed into COPD.
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nology, Wuhan, China.
SNPs selection and linkage disequilibrium analysis
There were 5 single nucleotide polymorphisms (SNPs)
in or near HHIP (rs1980057, rs12504628, rs13147758,
rs13118928, rs1828591), 1SNP in IREB2 (rs13180) and
1SNP in FAM13A (rs7671167) genotyped in our study.
These have been reported to be associated with COPD
susceptibility or lung function in Caucasians and in the
meta-analysis studies were shown as probable risk gen-
etic variants related to COPD or lung function decline.
In meta-analysis, the SNPs in HHIP, FAM13A and
IREB2, which were reported in different study cohortsthat focused on lung function or COPD susceptibility
[10,19-22] were analyzed for their odds ratios (ORs) as
shown in Figure 2 (full details of meta-analyses can be
accessed in Additional file 1). Some of the cohorts ana-
lyses were performed in Chinese Han population in
these reports, however, the number of subjects was not
large enough [23,24]. Moreover, 60SNP markers with a
minor allele frequency (MAF) ≥0.05 in or near HHIP were
downloaded from HapMap (http://www.hapmap.org/)
for the Chinese Han population (Chinese Han from
Beijing–CHB). Tag SNPs were selected for the gene by
using Tagger in Haploview (http://www.broadinstitute.org/
haploview/haploview). Under the pair-wise mode used, a
minimal set of markers were selected. All the captured
Figure 2 The meta-analysis on the associations of SNPs with lung function or COPD susceptibility.
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tagged SNPs (rs7654947, rs11100865, rs6819412, rs7689420,
rs7675744, rs6826012, rs2639576, rs6812389, rs1489758)
were selected in the HHIP region in CHB. Taken together, a
total of 14SNPs in or near the HHIP, 1SNP in IREB2
and 1SNP in FAM13A were selected for genotyping in
our study.
The linkage disequilibrium (LD) between the SNPs in
the HHIP locus were examined with the Haploview 4.2
program (Broad Institute of MIT and Harvard, Boston,
MA, USA) for all control subjects [25].
Genotyping and quality control
Genomic DNA was extracted from peripheral venous
blood, which was drawn from each subject, after their
informed consent was obtained, by using the Blood Gen-
omic DNA Purification Kit (Tiangen Biotech, Beijing,
China) according to the manufacturer’s protocol. 16
single nucleotide polymorphisms (SNPs) in genes which
have been reported to be associated with COPD sus-
ceptibility or decreased lung function in Caucasians
[8,20,21,26] were chosen for the genotyping tests in all
subjects, who were genotyped using the TaqMan Geno-
typing system (Applied Biosystems, Foster City, CA)
without knowledge of the case or control status of thesubjects. The PCR were performed on the PCR 9700
machine (Applied Biosystems, Foster City, CA) under
the following conditions: 95°C for 10 min followed by
45 cycles of 92°C for 15 s and 60°C for 90s. After the
reactions were completed, the DNA chips were read
under Detection System of OpenArrayNT (BioTrove,
Baltimore, Maryland, United States). The data were an-
alyzed using the TaqMan Genotyper Software version
1.2 (Applied Biosystems, Foster City, CA). Subjects
with a call rate of < 95%, and SNPs with a call fre-
quency < 95% were removed.
Statistical analysis
The differences in the distribution of categorical vari-
ables in characteristics of subjects were tested using the
Pearson’s chi-square test and continuous variables by
Student’s t test. The Hardy–Weinberg equilibrium was
assessed by the goodness-of-fitness chi-square test to
compare the observed genotype frequencies to the ex-
pected genotype frequencies in the controls.
Logistic regression was used to evaluate the associa-
tions between SNPs of HHIP, IREB2 and FAM13A geno-
types and COPD susceptibility. The odds ratios (ORs)
and their 95% confidence intervals (CIs) were calculated
after adjustments for age, sex and smoking history. The
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ent genotypes of SNPs were inspected by student’s t test
when the data met the normal distribution and were
expressed as means ± SEMs. All statistical analyses were
conducted by using Statistical Package for the Social Sci-
ences (SPSS) version 19.0 software (SPSS Inc., Chicago,
IL, USA) or GraphPad Prism 5 software (GraphPad, San
Diego, CA).
Results
Characteristics of subjects in the study
Table 1 presents the characteristics of individuals partici-
pating in the study that included the 18-year follow-up
observations and the two replication cohorts. In the sub-
jects who completed the study, a total of 306 cases (286
males) and 743 controls (684 males) with a mean age of
46.07 ± 8.68 years in 1992 were enrolled in the first
stage. A total of 112 healthy subjects in 1992 were found
to have obstructive pulmonary ventilation disorders after
lung function tests in 2010 and this group of subjects we
designated as cases to compare with our controls. We
had 409 (385 males) cases and 611 controls (566 males)
with age of 63.70 ± 8.86 years who remained in the study
in 2010. We selected age- and gender- matched controls
for the cases in each group to perform the genotype
tests from the corresponding healthy group. The smok-
ing status and history of subjects in 1992 and 2010 were
nearly analogous between cases and controls and few
were non-smokers.
The replication cohorts, totaling 374 cases (304 males,
62.46 ± 9.28) and 377 controls (309 males, 61.39 ±
10.13), were from the rural cohort in 2010, and 541
cases (443 males, 65.73 ± 9.13) and 560 controls (445
males, 64.55 ± 9.86) were from the urban cohort in 2010.
There were no significant differences in the distribu-
tion of age and gender between cases and controls in
either group of subjects.Table 1 Characterististics of groups of study subjects
Variable Subjects in 1992 Subjects in2010 Su
fo
Cases Controls Cases Controls C
No. of subjects 306 743 409 611 11






























Post-FEV1 (±SD) 2.03 ± 0.52 2.82 ± 0.57 1.58 ± 0.62 2.43 ± 0.57 1.





















7.Genotypes and risk of COPD
In the first cohort, the regular smokers, who were con-
sidered to be in the risk groups of COPD, had lung func-
tion tests performed according to the same operational
standards every five years in Haokou. There were 306
COPD patients and 743 healthy controls at the begin-
ning of our study in 1992, but at the end of the study in
2010, there were 409 cases and 611 controls. Among the
cases in 2010, there were 112 individuals who had nor-
mal lung function and were part of the healthy control
group in 1992. Regardless of their status in 1992 or
2010, all subjects who had completed our study were ge-
notyped. We compared the genotypes of cases with their
gender- and age- matched healthy controls both in 1992
and 2010, especially for the cases from controls and
their control subjects who still had normal lung function
in 2010 (Table 2).
As shown in Table 2, there were 4SNPs (rs11100865,
rs12504628, rs13118928 and rs7654947) that occurred in
or near the HHIP and one SNP in FAM13A (rs7671167)
in different genotypes displaying significant differences
between cases and controls in 1992. These 4SNPs occur-
ring in HHIP were associated with increasing COPD risk
after adjusting for age, gender and smoking history. One
SNP in FAM13A, rs7671167, was observed as having
significant associations with an increased risk of COPD.
However, it was found that genotypes of 2SNPs in or
near HHIP (rs11100865 and rs7654947) and 1SNP in
FAM13A (rs7671167) were associated with an increased
risk of COPD in 2010. Among the 5SNPs identified in
subjects of 1992, rs12504628 and rs13118928 were not
significantly associated with an increased COPD risk in
2010. The SNPs in HHIP (rs11100865 and rs7654947)
and in FAM13A (rs7671167) were significantly associ-
ated with risk of COPD. A relationship with increased
COPD risk in the group subjects of cases from controls
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Subjects of 1992 Subjects of 2010 Subjects of Cases from Controls
GF(Cases/Contols) P OR(95% CI) GF(Cases/ Controls) P OR(95% CI) GF(Cases/ Controls) P OR(95% CI)
HHIP rs11100865 145870597 G→ A
GG 0.239/0.284 reference 0.229/0.299 reference 0.213/0.282 reference
AG 0.448/0.498 0.166 1.287(0.900-1.841) 0.477/0.492 0.262 1.266(0.838-1.912) 0.525/0.504 0.301 1.382(0.749-2.551)
AA 0.313/0.218 0.007 1.715(1.162-2.532) 0.294/0.209 0.001 1.925(1.214-2.687) 0.263/0.214 0.17 1.637(0.809-3.313)
rs12504628 145655774 T→ C
TT 0.500/0.506 reference 0.519/0.497 reference 0.550/0.493 reference
CT 0.351/0.421 0.383 0.829(0.543-1.264) 0.360/0.430 0.265 0.815(0.569-1.168) 0.375/0.430 0.477 0.829(0.493-1.392)
CC 0.149/0.073 0.018 2.114(1.136-3.935) 0.121/0.072 0.116 1.597(0.891-2.863) 0.075/0.074 0.81 0.890(0.436-2.291)
rs13118928 145705839 A→ G
AA 0.470/0.457 reference 0.495/0.441 reference 0.538/0.446 reference
AG 0.373/0.459 0.298 0.801(0.527-1.217) 0.379/0.474 0.069 0.718(0.502-1.026) 0.389/0.475 0.148 0.685(0.410-1.143)
GG 0.158/0.083 0.048 1.839(1.005-3.365) 0.126/0.085 0.317 1.334(0.758-2.348) 0.075/0.079 0.629 0.792(0.309-2.035)
rs7654947 145845180 T→ C
TT 0.321/0.417 reference 0.327/0.433 reference 0.338/0.441 reference
CT 0.440/0.402 0.112 1.433(0.920-2.235) 0.453/0.387 0.023 1.552(1.062-2.267) 0.475/0.372 0.042 1.750(1.020-3.001)
CC 0.239/0.182 0.027 1.820(1.070-3.096) 0.220/0.180 0.004 1.882(1.192-2.816) 0.188/0.166 0.039 1.842(1.201-2.568)
FAM13A rs7671167 90103002 T→ C
TT 0.313/0.252 reference 0.322/0.235 reference 0.338/0.224 reference
CT 0.463/0.442 0.43 0.832(0.527-1.314) 0.463/0.438 0.222 0.779(0.522-1.163) 0.463/0.443 0.426 0.791(0.443-1.411)
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revealed similar results as in subjects of 2010 displaying
an association with increased COPD risk. No significant
differences were found in the other 3SNPs in HHIP.
In the 18 years of observations, some of the subjects
had changed their status from healthy controls to COPD
with their genetic differences playing critical roles. We
analyzed the relationship of genotypes and COPD by
comparing the different SNPs genotypes and COPD sta-
tus, especially for subjects who, over the study period,
had developed obstructive ventilatory dysfunction from
normal subjects in the study. Figure 3 demonstrates the
SNPs in genotypes which were associated with COPD
risk were selected out in different groups, and the com-
mon genetic variants were considered to be more cor-
relative to risk of COPD. We followed the subjects and
examined their lung functions for 18 years and com-
pared genotypes of the SNPs in each group of our study
to reduce the bias that can arise from cross-sectional
studies. Finally, 2SNPs in HHIP (rs11100865 and
rs7654947) and 1SNP in FAM13A (rs7671167) were
considered as being associated with COPD susceptibility
in the Chinese Han population.
In the replication cohorts, 12SNPs were successfully
genotyped. Among the five SNPs which were identified
as being associated with increased COPD risk in either
group of subjects in the first stage, it was shown that the
genotypes in rs11100865, rs7654947 and rs7671167 were
associated with risk of this disease in both the rural rep-
lication cohort and the urban cohort. This result was
consistent with the cohort study in the first stage. Add-
itionally, in urban replication cohort, the genotypes of
rs13118928 were also observed as associating with an in-
creased COPD risk.
In 2010, a total of 1,333 COPD cases and 1,552 con-
trols in both stages of our study were added together to
replicate the identified SNPs in the entire population of
our study. Table 3 shows that rs11100865 and rs7654947
in HHIP and rs7671167 in FAM13A were also associated
with an increased risk of COPD, and this was consistent
with the discovery at the first stage which revealed the
same SNPs in loci associated with COPD susceptibility.
Each of these SNPs in all control subjects was in Hardy-
Weinberg equilibrium.
Based on the 18-year follow-up and the two replica-
tion cohorts, we identified two new loci (rs11100865 and
rs7654947) that were associated with increased COPD
susceptibility, and confirmed that one loci (rs7671167)
in FAM13A was associated with the development of
COPD in Chinese Han population.
The linkage disequilibrium among these SNPs in the
HHIP region, which were identified as probably being
associated with increased COPD susceptibility, is shown
in Figure 4. The LD values were examined in all healthycontrols in 2010 which includes the two replication co-
horts are presented as r2.Association between decline in FEV1 and SNPs genotypes
In our research, the FEV1 decline in every subject over
the 18 years is variable for different SNPs genotypes.
The FEV1 decline in each genotype from the 18-year
follow-up observations is shown in Figure 5. In
rs7654947, the FEV1 decreases were higher in those CC
or CT subjects than TT. There were significant differ-
ences in the groups of cases and controls in 1992 and
cases in 2010 (p<0.05). In rs7671167, the FEV1 decreases
occurred more frequently in CC subjects compared with
CT or TT in cases from the controls. The difference was
statistically significant (p = 0.0059). The decrease of
FEV1 in other SNPs in different genotypes showed no
significant differences in either group of subjects. The
remaining 14 loci were not associated with a decline of
pulmonary function (data not shown).
In Figure 6, the association of the identified COPD
risk genetic variants, with a FEV1 decline in follow-up
individuals, in replication cohorts is demonstrated. The
individuals with CT and CC alleles in the rural replica-
tion cohort cases and CC in the urban replication cases
of rs7654947 showed a greater FEV1 decline compared
with the TT subjects. In rs7671167, the cases in rural
replication cohort with the CC allele had a greater FEV1
decline compared to cases with the TT allele. In either
replication cohorts (rural or urban), there was no signifi-
cant differences in genotypes on the decline of FEV1 in
other SNPs. This result was consistent with the associ-
ation of FEV1 decline with the COPD risk variants in the
first 18-year follow-up stage.
Based on our 18-year follow-up and 2-year follow-up
in the two replication cohorts, we have identified one
new loci (rs7654947 in HHIP) that was associated with
lung function decline, and one loci (rs7671167 in
FAM13A) that was associated with lung function decline
and was consistent with previous research performed on
Caucasians [21].Discussion
In our genome-wide association study on gene suscepti-
bility of COPD comprising 306 COPD and 743 control
subjects in an 18-year follow-up population, and 915
COPD patients with 937 controls in two replication co-
horts of a 2-year follow-up, a total longitudinal of 1,333
COPD cases and 1,552 controls were recruited in this
study. Two new loci (rs11100865 and rs7654947) in
HHIP and one SNP (rs7671167) in FAM13A were iden-
tified as being associated with increased COPD risk. The
SNP of rs7654947 (a new locus) in HHIP was associated
with FEV1 decline after the 18-year follow-up observation
Figure 3 The genetic variants identified as being associated with increased COPD risk in different groups of subjects of the follow-up stage. In
different periods of the first stage, the COPD risk variants were identified by genotype comparison of COPD subjects with healthy controls who
were at COPD risk. By contrast, the common variants were considered to have less bias and to be more reliable. Since the cases from controls
and their healthy controls in 2010 were part of the control individuals in 1992, some COPD risk variants may be not be identified.
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horts. These differences were statistically significant.
This is the first time that a longitudinal 18 years study
was applied to the gene susceptibility of COPD and lung
function decline, and to demonstrate two new SNPs in
HHIP that associated with COPD susceptibility. Neverthe-
less, the two other SNPs (rs12504628 and rs13118928) at
the HHIP locus associated with risk of COPD in subjects
of 1992 in the follow-up population, were previously
shown to be associated with lung function and risk ofdeveloping COPD in Caucasians [19,22,27] and rs12504628
in Chinese Han population [28]. However, none of them
were determined to have significant associations with lung
function or COPD risk in both of the replication co-
horts or the entire population. Thus, no significant dif-
ference appeared in the FEV1 decline of individuals in
different genotypes of them, in the 18 years follow-up.
Distinguishable from other GWAS performed on cross-
sectional cohorts, our study is based on a prospective
follow-up cohort that lasted for 18 years and has





Rural replication cohort Urban replication cohort Subjects of all Cases and Controls HWE
p-
value
GF(Cases/Contols) P OR(95% CI) GF(Cases/Controls) P OR(95% CI) GF(Cases/Controls) P OR(95% CI)
HHIP rs11100865 145870597 G→ A 0.229
GG 0.291/0.304 reference 0.297/0.380 reference 0.282/0.334 reference










rs12504628 145655774 T→ C 0.314
TT 0.489/0.513 reference 0.518/0.477 reference 0.509/0.493 reference










rs13118928 145705839 A→ G 0.875
AA 0.486/0.479 reference 0.535/0.504 reference 0.511/0.478 reference










rs7654947 145845180 T→ C 0.370
TT 0.369/0.514 reference 0.351/0.309 reference 0.352/0.406 reference










FAM13A rs7671167 90103002 T→ C 0.205
TT 0.288/0.232 reference 0.323/0.266 reference 0.312/0.247 reference



















Figure 4 The LD values of the probable COPD risk variants in HHIP identified in all controls of our study.
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creased COPD risk.
There are many common genetic variants in the loci
of chromosomes 4 (HHIP and FAM13A) [21] and 15
(CHRNA3/5 and IREB2) [6,29] that display roles in the
development of COPD, and the CHRNA3/5 locus that is
associated with smoking addiction [10] which results in
smoking-related lung diseases, such as COPD and lung
cancer. Pillai et al reported that HHIP variants were
associated with the systemic components and the fre-
quency of exacerbations in individuals with COPD,
and FAM13A had evidence for an association with
lung function and emphysema in COPD patients [10].
Zhou et al demonstrated that SNPs near HHIP were
strongly associated with pulmonary function levels and
moderate-to-severe COPD in a Polish cohort [26]. A
GWA study in the Framingham Heart Study reported
that SNPs in or near HHIP were associated with lungfunction and the SNPs were different from these de-
scribed above [11]. Cho et al reported that variants in
FAM13A were not associated with pack-years of
cigarette smoking but contributed to the development
of COPD [21]. The lung function decline could also be
displayed in other respiratory diseases such as asthma
in addition to COPD. Both COPD and asthma share
the common feature of a strong heritability for FEV1
with twin studies focused on lung function [30] and
genetic loci were identified for COPD, asthma and
lung function in GWAS. Among these, HHIP and
FAM13A are associated with both COPD and lung
function in individuals of European ancestry. Our
study selected the SNPs frequently being identified as
associating with COPD or lung function in Caucasians.
Of these, we performed a meta-analysis that show
them to be potentially COPD risk variants and also se-
lected out those SNPs downloaded from HapMap for
Figure 5 The FEV1 decline in different genotypes of subjects in the first stage of the 18-year follow-up. A. FEV1 decline in different genotypes of
rs7654947. B. FEV1 decline in different genotypes of rs7671167. C. FEV1 decline in different genotypes of rs11000865. D. FEV1 decline in different
genotypes of rs12504628. E. FEV1 decline in different genotypes of rs13118928.
# p < 0.05 represents the statistical difference between individuals
of different genotypes in groups of subjects.
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at the HHIP locus and 1SNP (rs7671167) at FAM13A,
which were chosen from those associated with an in-
creased risk of COPD or lung function previously re-
ported in Caucasians [19-22,27], were also associated with
an increased risk of COPD in cross-sectional individuals,
in 1992. However, only rs7671167 in FAM13A was suc-
cessfully replicated in both the rural and urban replication
cohorts. In these SNPs, which were selected from the
downloaded HapMap for CHB, both of rs11100865 and
rs7654947 in HHIP were identified as being associated
with an increased risk of COPD in the longitudinal stage
and the two replication cohorts.
Some of the healthy control subjects in 1992 devel-
oped into COPD after 18 years follow-up. After compar-
isons of the different groups of subjects associated with
COPD susceptibility, the bias on the cross-sectional
GWA study could be reduced when the relationship of
genetic variants and COPD was estimated in our longitu-
dinal stage. To determine the relationship of lung function
decline and the genetic variants identified associating with
COPD susceptibility in our study, we followed-up the sub-
jects recruited in 1992 in pulmonary function observation
for 18 years instead of cross-sectional lung functionparameters analyzed in the GWA study. FEV1 is a main
parameter to classify the severity of obstructive pulmonary
disease and to follow its progress [31]. The FEV1 decreases
in different genotypes of the genetic variants, which were
possibly associated with COPD risk, were compared to
each other to disclose the relationship of deterioration of
lung function with different genotypes. Through the
follow-up observation of pulmonary function decline in
subjects in 18 years, the relationship of lung function and
genetic variants identified in our study would be more ob-
jective and credible. Among the 4SNPs in HHIP and
1SNP in FAM13A, which were demonstrated as being re-
lated to COPD susceptibility, the genotypes of rs7654947
in HHIP and rs7671167 in FAM13A in FEV1 decline were
significantly different in cases or controls of the follow-up
cohort. Additionally, there were no significant differences
detected of FEV1 decline in any group of cases or control
subjects with genotypes of rs12504628 and rs13118928 in
HHIP. Since the first GWA studies focused on lung func-
tion in the Framingham Heart Study [9], there are several
large-scale research efforts involving a large number of
participants in associated studies between genetic variants
and lung function. The majority of these studies were
cross-sectional analyses of lung function associated with
Figure 6 The FEV1 decline in different genotypes of individuals in replication cohorts in the 2-year follow-up. A. FEV1 decline in different genotypes of
rs7654947 in replication cohorts. B. FEV1 decline in different genotypes of rs7671167 in replication cohorts. C. FEV1 decline in different genotypes of
rs11000865 in replication cohorts. D. FEV1 decline in different genotypes of rs12504628 in replication cohorts. E. FEV1 decline in different genotypes of
rs13118928 in replication cohorts. # p < 0.05, and * p<0.01, represent statistical difference in different genotypes of the follow-up replication subjects.
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were carried out in follow-up cohorts to establish the
novel loci influencing lung function [7,15], and the decline
of lung function in participants were mainly confined in
healthy individuals. The development of COPD takes time
and the follow-up measures of lung function in our study
lasted for 18 years, and allowed the monitoring of COPD
development per 5 years for this period. Moreover, sub-
jects in our follow-up stage were COPD patients or
healthy individuals at risk of COPD, who were addicted to
cigarette smoking. There is no follow-up research focused
on the decline of lung function in participants who were
at risk of or was already suffering from COPD except for
ours until this report.
Moreover, in our 18-year longitudinal prospective
study, we not only observed the decline of lung function
in COPD and healthy controls who were COPD risk in-
dividuals, but we also identified the COPD susceptibility
loci and their relationship with lung function. Distin-
guishable from other GWA studies on cross-sectional
cohorts, our study was performed on a longitudinal pro-
spective cohort and was replicated in rural and urban
cohorts. The genetic variants were identified as beingassociated with an increased risk of COPD in the sub-
jects between cases and controls in 1992. After 18 years,
some of the COPD risk healthy controls in 1992 were di-
agnosed COPD after the lung function measurements in
2010 accompanied with those still in health without any
interventions of cigarette smoking. The genetic variants
which are associated with an increased COPD risk are
considered to play important roles in the development
of COPD. The identification of variants associated with
increased COPD risk was also applied in populations of
newly developed COPD patients and controls similar to
the cases and controls in 2010. The common genetic
variants of these identifications are possibly more cred-
ible for bias on the cross-sectional studies and would re-
duce these to a minimum. This was the first study to
perform a genome-wide association examination on dis-
eases that relate to genetic predispositions in a prospect-
ive study that was focused on the same population with
18 years of follow-up observations.
In the replication stage, there were two replication
cohorts in which individuals were from rural and
urban areas in Hubei, China respectively. These were
carried on individuals from different environmental
Xie et al. Respiratory Research  (2015) 16:49 Page 13 of 14and living conditions to replicate the association of
the polymorphisms of SNPs which were identified in
the prospective stage with the risk of COPD in different cir-
cumstances and areas. COPD is a chronic pulmonary dis-
ease that involved the chronic inflammation in airways,
which is a complex disease strongly affected by circum-
stance for the lung, including smoking addition, and genetic
predisposition. Besides cigarette smoking, air conditions
and certain living lifestyles may also influence the preva-
lence of COPD. As we have already adjusted for smoking
history in our study, it was necessary to confirm the associ-
ation of genetic variants in the regions with COPD in dif-
ferent circumstances for living in the replication stage.
Thus, the replication stage in our study was performed in
rural and urban areas to be more authentic and reliable.
However, the limitation in this study is that changes in
smoking habits over time may effect lung function, and
the benefits of smoking cessation in attenuating pulmon-
ary function decline have been previously studied exten-
sively [32]. Unfortunately, our study at present was not
adequate to further confirm whether altering smoking
habits is associated with changes in lung function. Since
we recruited participants with smoking history of more
than 20 pack-years and performed non-intervention in
cigarette smoking during the follow-ups, all the subjects
in each group of our study had nearly analogous smok-
ing history. In addition, our study covered extensive
follow-up data including a total of 2872 subjects, three
different areas in china, 18- or 2-year follow-up observa-
tions. Despite this limitation, our study was adequately
powered to identify the association between the two
SNPs (rs7654947 and rs7671167) and lung function
decline.
Conclusions
Our genome-wide survey identified 2 new SNPs
(rs11100865 and rs7654947) in HHIP that were associated
with COPD susceptibility. Moreover, we found rs7654947
in HHIP and rs7671167 in FAM13A were related to decline
in lung function. For the first time, we used a longitudinal
prospective study with 18-year follow-up observations, to
identify new loci both associated with COPD susceptibility
and lung function decline in a Chinese Han population.
Further GWAS will be required to investigate more candi-
date SNPs for COPD risk prediction.Additional file
Additional file 1: Methods: Specific details of meta-analyses in SNPs
selected part.
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